The advent of poly(ADP-ribose) polymerase inhibitors (PARPi) has revolutionized the treatment landscape for cancers harboring homologous recombination (HR) deficiencies, particularly those resulting from BRCA1 and BRCA2 mutations1. This evidence concerns the gene BRCA2 and cancer.